Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Clin |
RCV000851822 | SCV001809918 | pathogenic | Glanzmann thrombasthenia | 2021-05-07 | reviewed by expert panel | curation | The NM_000419.5(ITGA2B):c.559del (p.Val187TrpfsTer37) frameshift variant has been reported homozygous in at least 2 GT probands (PMIDs: 19691478, 31064749). It is predicted to undergo NMD due to creation of a premature stop codon in exon 7. The overall allele frequency in gnomAD is extremely low at 0.000004723, with a MAF of 0.00003507 in the South Asian population. In summary, this variant meets criteria to be classified as Pathogenic for GT. GT-specific criteria applied: PVS1, PM2_supporting, PM3_supporting, and PP4_moderate. |
NIHR Bioresource Rare Diseases, |
RCV000851822 | SCV000899806 | pathogenic | Glanzmann thrombasthenia | 2019-02-01 | criteria provided, single submitter | research | |
ISTH- |
RCV002222050 | SCV002499592 | likely pathogenic | Glanzmann thrombasthenia 1 | criteria provided, single submitter | clinical testing | ||
Labcorp Genetics |
RCV000851822 | SCV004491995 | pathogenic | Glanzmann thrombasthenia | 2023-06-04 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 627093). This premature translational stop signal has been observed in individual(s) with Glanzmann thrombasthenia (PMID: 19691478). This variant is present in population databases (no rsID available, gnomAD 0.003%). This sequence change creates a premature translational stop signal (p.Val187Trpfs*37) in the ITGA2B gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ITGA2B are known to be pathogenic (PMID: 21917754). |